Cargando…
Efficacy and safety of tofacitinib for the treatment of chronic plaque psoriasis: a systematic review and meta-analysis
BACKGROUND: Tofacitinib is an oral Janus kinase (JAK) inhibitor that targets JAK1 and JAK3, and thus regulates immune response. Therefore, tofacitinib is used to treat immune-mediated inflammatory diseases such as chronic plaque psoriasis. The objective of this study was to systematically assess the...
Autores principales: | Tian, Fangyuan, Chen, Zhaoyan, Xu, Ting |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6567701/ https://www.ncbi.nlm.nih.gov/pubmed/31096817 http://dx.doi.org/10.1177/0300060519847414 |
Ejemplares similares
-
Bimekizumab for the treatment of moderate-to-severe plaque psoriasis: a meta-analysis of randomized clinical trials
por: Wang, Yuqian, et al.
Publicado: (2023) -
Comparative efficacy of secukinumab against adalimumab and infliximab in patients with moderate-to-severe plaque psoriasis
por: Pan, Ran, et al.
Publicado: (2022) -
Real-world experience with tofacitinib in ulcerative colitis: a systematic review and meta-analysis
por: Lucaciu, Laura A., et al.
Publicado: (2021) -
Impact of smoking on psoriasis risk and treatment efficacy: a
meta-analysis
por: Zhou, Hang, et al.
Publicado: (2020) -
Efficacy and safety of Huangqi Jianzhong decoction in the treatment of chronic atrophic gastritis: A meta-analysis
por: Yan, Xin-Peng, et al.
Publicado: (2023)